"目录号: HY-15284A
GPCR/G Protein-
Prasugrel盐酸盐是血小板抑制剂，IC50为1.8 μM。
P2Y Receptor
相关产品
Suramin sodium salt-Clopidogrel hydrogen sulfate-Ticagrelor-MRS 2578-Prasugrel-AZD1283-N6-(4-Hydroxybenzyl)adenosine-Diquafosol tetrasodium-Denufosol tetrasodium-
生物活性
Description
Prasugrel hydrochloride is a platelet inhibitor with IC50 value of 1.8 μM.Target: P2Y12 receptorPrasugrel hydrochloride is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI [2].Prasugrel hydrochloride reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel hydrochloride AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 Μm [2]. Clinical indications: Acute coronary syndrome; Ischemic heart disease; Sickle cell anemia; Stroke; Vascular occlusive diseaseFDA Approved Date: February 2009Toxicity: Hypertension; Headache; Hypercholesterolemia/hyperlipidemia; Nausea; Epistaxis
Clinical Trial
NCT02212028
University of Florida
Coronary Artery Disease
October 2014
Phase 4
NCT01493999
University of Pecs
Acute Coronary Syndrome
September 2011
Phase 4
NCT01260584
Daiichi Sankyo Inc.
Coronary Artery Disease
November 2010
Phase 4
NCT01476696
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Disease
November 2011
Phase 2
NCT01560780
VA Office of Research and Development
Coronary Artery Bypass
February 1, 2013
Phase 3
NCT01115738
Eli Lilly and Company
Acute Coronary Syndrome
May 2010
Phase 2
NCT01014624
Daiichi Sankyo Inc.
Coronary Artery Disease
February 2010
Phase 4
NCT01201772
University of Florida
Coronary Artery Disease
August 2010
Phase 4
NCT01835353
University of Patras
Platelet Reactivity
June 2012
Phase 3
NCT01178099
Eli Lilly and Company-Daiichi Sankyo Co., Ltd.
Anemia, Sickle Cell
July 2010
Phase 1
NCT01852175
University of Florida
Coronary Artery Disease
January 2012
NCT01852214
University of Florida
Diabetes Mellitus-Coronary Artery Disease
February 2013
NCT01365221
Medstar Health Research Institute
Acute Coronary Syndrome
December 2010
Phase 4
NCT01531114
Gennaro Sardella-University of Roma La Sapienza
ST-Elevation Myocardial Infarction
May 2013
Phase 3
NCT01641510
Dong-A University
Acute Coronary Syndromes
October 2013
Phase 3
NCT01591317
Eli Lilly and Company
Healthy Volunteers
March 2009
Phase 1
NCT02070159
Dong-A University
Coronary Artery Disease
December 2011
Phase 3
NCT01465828
Gennaro Sardella-University of Roma La Sapienza
Acute Coronary Syndrome
October 2011
Phase 3
NCT02075125
Dong-A University
ST-Segment Elevation Myocardial Infarction
January 2014
Phase 3
NCT01778842
Gennaro Sardella-University of Roma La Sapienza
Coronary Artery Disease
March 2013
Phase 3
NCT01876797
Asan Medical Center
Healthy
July 2013
Phase 1
NCT01852019
The Medicines Company
Coronary Artery Disease
June 2013
Phase 2
NCT01430091
Eli Lilly and Company
Sickle Cell Disease
September 2011
Phase 1
NCT01951001
Gyeongsang National University Hospital
Acute Coronary Syndrome-Platelet Thrombus-Bleeding
July 2013
Phase 4
NCT02065479
University of Florida
Coronary Artery Disease
March 2014
Phase 4
NCT02808767
Faculty Hospital Kralovske Vinohrady
Myocardial Infarction-Angioplasty, Balloon, Coronary-Platelet Aggregation Inhibitors
January 2013
Phase 4
NCT00385944
Eli Lilly and Company-Daiichi Sankyo Inc.
Acute Coronary Syndrome
March 2007
Phase 2
NCT01304472
University of Patras
Coronary Artery Disease (CAD)
February 2011
Phase 3
NCT01790854
David Antoniucci-A.R. CARD Onlus Foundation-Careggi Hospital
Adverse Reaction to Antiplatelet Agent-Acute Coronary Syndrome
November 2012
Phase 4
NCT01609647
Dong-A University
Acute Coronary Syndrome
September 2012
Phase 3
NCT01789814
Tufts Medical Center
Coronary Artery Disease
July 2013
Phase 4
NCT01587651
Daiichi Sankyo Inc.-Eli Lilly and Company
Coronary Artery Disease
March 2012
Phase 4
NCT02016170
University of Florida
Coronary Artery Disease-Acute Coronary Syndrome
March 2014
NCT01155765
University of Patras
Hemodialysis-Chronic Renal Failure
May 2010
Phase 3
NCT01648790
Eli Lilly and Company-Daiichi Sankyo Inc.
Healthy Volunteers
July 2012
Phase 1
NCT01109784
University of Patras
Coronary Artery Disease (CAD)-Acute Coronary Syndrome (ACS)
April 2010
Phase 3
NCT02507323
Yochai Birnbaum-AstraZeneca-Baylor College of Medicine
Cardiovascular Disease
February 2016
Phase 2
NCT01463150
University of Patras
Platelet Reactivity
October 2011
Phase 4
NCT01456364
Deutsches Herzzentrum Muenchen
Coronary Heart Disease
September 2011
Phase 4
NCT01684813
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Andaluz Health Service
Diabetes Mellitus Type II-Acute Coronary Syndrome
October 2012
Phase 4
NCT01167023
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Anemia
July 2010
Phase 2
NCT01463163
University of Patras
Platelet Reactivity
October 2011
Phase 4
NCT01794000
Eli Lilly and Company-Daiichi Sankyo Inc.
Sickle Cell Disease
April 2013
Phase 3
NCT02075268
Asan Medical Center
Healthy
January 2014
Phase 1
NCT02215993
Federal University of São Paulo
Acute Coronary Syndrome-Platelet Function
July 2013
Phase 4
NCT01543932
University of Roma La Sapienza
Coronary Artery Disease
July 2012
Phase 3
NCT02193971
Seoul National University Hospital-Boston Scientific Korea Co. Ltd-Dio-Terumo Corporation
Acute Coronary Syndrome
July 2014
Phase 4
NCT01338909
University of Patras
Myocardial Infarction
April 2011
Phase 3
NCT01869309
LifeBridge Health-AstraZeneca
Coronary Artery Disease
January 2014
Phase 4
NCT01774838
University of Cologne
Acute Coronary Syndrome-Unstable Angina
October 2014
Phase 3
NCT01944800
Deutsches Herzzentrum Muenchen-Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
Acute Coronary Syndrome (ACS)
September 2013